GLP-1 类似物利拉鲁肽联合门冬胰岛素30 对2 型糖尿病患者认知功能障碍的影响

Effect of GLP-1 receptor agonist combined with insulin aspart30 on cognitive impairment of patients with type 2 diabetes mellitus

摘要:

目的 探究GLP-1 类似物利拉鲁肽联合门冬胰岛素30 治疗2 型糖尿病患者认知功能障碍的临床 疗效。方法 连续入选2014 年9 月-2016 年1 月山东省滕州市中心人民医院内住院的2 型糖尿病患者132 例， 将患者随机分成门冬胰岛素30 治疗组（对照组，66 例）和利拉鲁肽联合门冬胰岛素30 治疗组（实验组，66 例），治疗1 年后随访结果，比较分析治疗前后两组患者血糖、血脂、体重指数及认知功能的变化情况。结果 治疗1 年后随访，实验组的血糖、体重指数较对照组改善，认知功能量表MMSE、MoCA、CMS 总分均高于 对照组（P <0.05）。结论 利拉鲁肽联合门冬胰岛素30 在控制血糖、降血脂、改善体重指数方面的临床疗效 优于单纯的门冬胰岛素30，且有效改善糖尿病患者认知功能。

Abstract:

Objective To investigate the effect of glucagon-like peptide-1 (GLP-1) receptor agonist Liraglutide combined with insulin aspart 30 on the cognitive impairment of the patients with type 2 diabetes mellitus. Methods A total of 132 consecutive patients with type 2 diabetes mellitus in our hospital between September 2014 and January 2016 were recruited. The patients were randomly divided into two treatment groups: insulin aspart 30 group (control group, 66 cases), Liraglutide combined with insulin aspart 30 group (research group, 66 cases). The patients were followed up 1 y after treatment. The changes of blood glucose, lipid biochemical indexes, body mass index (BMI) and cognitive function before and after treatment were compared between the two groups. Results The follow-up results showed that glucose and BMI in the research group were improved when compared with the control group, and the total scores of cognitive function scales MMSE, MoCA and CMS were higher than those in the control group (P < 0.05). Conclusions Liraglutide combined with insulin aspart 30 has better clinical curative effect in the control of blood glucose, reducing blood lipids and improving BMI than insulin aspart 30 alone, and it can also improve the cognitive function of the patients with diabetes mellitus.